A Phase 2, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF)containing Regimens inSubjects with Chronic HBV Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 13 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Jun 2017 Planned number of patients changed from 60 to 50.
- 03 Mar 2017 Planned End Date changed from 1 Jan 2020 to 1 Jun 2020.